Brief: Northstrive Biosciences Signs Definitive License Agreement For Commercialization Of El-22 And El-32
11/02/2026 12:46
Feb 11 (Reuters) - PMGC Holdings Inc ELAB.O: NORTHSTRIVE BIOSCIENCES SIGNS DEFINITIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF EL-22 AND EL-32, A MYOSTATIN-ENGINEERED PROBIOTIC FOR MUSCLE PRESERVATION IN ANIMAL HEALTH Source text: ID:nGNX5PCB0T Further company coverage: ELAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PMGC Holdings
See all newsBrief: PMGC Announces DBA As NorthStrive Holdings Trademark License Agreement, & Website Update
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
Pmgc Holdings Rises As Unit Expands Rights To Ai: discovered obesity, heart disease drug program